

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/36609 A1

(51) International Patent Classification⁷: C12N 9/48,
9/72, 9/68, A61K 38/48

(74) Agent: HAYZER, J., D.; Womble Carlyle Sandridge & Rice, PLLC, P.O. Box 725388, Atlanta, GA 31139-9388 (US).

(21) International Application Number: PCT/US00/31115

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date:
13 November 2000 (13.11.2000)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/438,331 13 November 1999 (13.11.1999) US

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US Not furnished (CIP)
Filed on Not furnished

(71) Applicant (for all designated States except US): BAYER CORPORATION [US/US]; 100 Bayer Road, Pittsburgh, PA 15205 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NOVOKHATNY, Valery, B. [UA/US]; 4617 Wee Burn Trail, Raleigh, NC 27612 (US). JESMOK, Gary, J. [US/US]; 485 Carlson Street, Richmond, NC 294805 (US). LANDSKRONER, Kyle, A. [US/US]; 70A E. Blithedale Avenue, Mill Valley, CA 94941 (US). TAYLOR, Kathryn, K. [US/US]; 2408 Flints Pond Circle, Apex, NC 27502 (US). ZIMMERMAN, Thomas, P. [US/US]; 6209 Braes Meadow, Raleigh, NC 27612 (US).



WO 01/36609 A1

(54) Title: METHOD OF THROMBOLYSIS BY LOCAL DELIVERY OF REVERSIBLY INACTIVATED ACIDIFIED PLASMIN

(57) Abstract: Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.

5

**METHOD OF THROMBOLYSIS BY LOCAL DELIVERY OF
REVERSIBLY INACTIVATED ACIDIFIED PLASMIN**

Reference to Related Application

10 This application is a continuation-in-part of U.S. patent application Serial No. 09/438,331, filed November 13, 1999.

Field of the Invention

15 The present invention relates generally to a method of thrombolysis using reversibly inactivated acidified plasmin that is substantially free of plasminogen activators and its local delivery of the acidified plasmin proximal to, or directly within, a thrombus. The therapeutic method is particularly applicable to the dissolution of thrombi wherever catheter-directed delivery is feasible.

Background

20 Thrombotic disease is a major cause of morbidity and mortality in the modern world. Acute myocardial infarction and ischemic stroke are the first and third causes of death and disability in Western societies. Occlusive thrombosis results in loss of blood flow to vital organs producing local oxygen deprivation, cell necrosis and loss of organ function. There are major benefits to the rapid destruction of a thrombus, 25 resulting in early re-canalization: it prevents cell death, reduces infarct size, preserves

organ function, and reduces early and late mortality. Thrombolytic therapy is now administered to more than 750,000 patients per year worldwide, while many times that number could potentially benefit from such treatment.

Thrombolytic agents now used in the lysis of occlusive blood clots are 5 plasminogen activators. Several different plasminogen activators are currently available for immediate clinical use and several new generation plasminogen activators are the subject of clinical testing: tissue plasminogen activator, tPA, and its second generation successor TNK-tPA, RETEPLASE™ (a deletion mutant of tPA), single chain urokinase-type plasminogen activator (scuPA, or pro-urokinase), 10 urokinase (UK), streptokinase (SK), and anisoylated plasminogen streptokinase activator complex (APSAC). tPA, scuPA, and UK are normally to be found at low levels in humans. Streptokinase is a bacterial enzyme with a powerful thrombolytic activity. APSAC is an isolated streptokinase-plasminogen complex. In all cases the plasminogen activators are capable of converting the zymogen plasminogen to the 15 active protease plasmin. The advantage offered by tPA and scuPA (and, to a lesser degree, APSAC) is that their activation of plasminogen is fibrin specific; binding to fibrin is a prerequisite for their full proteolytic activity to be realized (*Haber et al.*, 1989). Urokinase and streptokinase can activate plasminogen in the absence of fibrin. Such variation in the affinity for fibrin has important consequences as to the extent to 20 which systemic bleeding occurs in animal models; these differences, however, have not been appreciated clinically.

Plasminogen activators universally exert their thrombolytic potential by activating circulating zymogen plasminogen into plasmin. Plasmin, the principle fibrinolytic enzyme in mammals is a serine protease with trypsin-like specificity that

is derived from the inactive zymogen precursor plasminogen circulating in plasma. Plasminogen itself is a 791 amino acid polypeptide having an N-terminus glutamate residue. Plasminogen activators such as tissue plasminogen activator (tPA) or urokinase will cleave the single-chain plasminogen molecule, to produce active 5 plasmin, at the Arg⁵⁶¹-Val⁵⁶² peptide bond. The resulting two polypeptide chains of plasmin are held together by two interchain disulfide bridges. The light chain of 25 kDa carries the catalytic center and is homologous to trypsin and other serine proteases. The heavy chain (60 kDa) consists of five triple-loop kringle structures with highly similar amino acid sequences. Some of these kringles contain so-called 10 lysine-binding sites that are responsible for plasminogen and plasmin interaction with fibrin, α_2 -antiplasmin or other proteins.

The inherent problem with the therapeutic use of existing plasminogen activators such as tPA, UK and SK is bleeding complications associated with their use, including, for example, gastrointestinal hemorrhage in up to 20% of patients. 15 Intracranial hemorrhage, which is clinically the most serious, is a frequent and lethal side effect of current thrombolytic therapy, and occurs in approximately 1% of patients. The mechanism for bleeding is multifactorial and is believed to be due to unmasking of a vascular injury by lysis of a protective hemostatic plug and consequent loss of vascular integrity. This is combined with the systemic activation 20 of the fibrinolytic system and its attendant depletion of clotting factors. The focus of much recent research has been on generating modified plasminogen activators that exhibit improved fibrin specificity; this was expected to reduce the amount of bleeding complications. In some cases, these novel activators tend to preserve the circulating levels of such clotting factors such as fibrinogen, Factors VIII and V,

plasminogen, and α_2 -antiplasmin. They specifically target and bind to the fibrin molecules that reside in a thrombus, and will only act upon plasminogen when so bound. This has the result that plasminogen is cleaved to the active protease plasmin only in the vicinity of the thrombosis and the level of non-specific systemic cleavage 5 of fibrin is reduced. However, the number of bleeding complications with these new plasminogen activators remains significant.

The clinical success for thrombolytic drugs such as tissue plasminogen activator (tPA), streptokinase and urokinase in reducing the extent of a thrombotic occlusion of a vascular vessel is established. Plasminogen activators have therefore 10 become a treatment of choice in the management of acute myocardial infarction and some other thrombotic conditions. Nevertheless, various disorders, including myocardial infarction, occlusive stroke, deep venous thrombosis and peripheral arterial disease, remain a serious clinical problem and the known plasminogen activators currently used suffer from several limitations that impact their overall 15 usefulness in the elimination of a thrombus. In myocardial infarction, vascular flow is restored within 90 minutes in approximately 50% of patients, while acute coronary re-occlusion occurs in roughly 10% of patients. Coronary recanalization requires on average 45 minutes or more. Residual mortality, principally due to intracerebral hemorrhage, is still at least 50% of the mortality level in the absence of thrombolysis 20 treatment.

Most research in the area of thrombolytics has focused on improving the efficacy and fibrin specificity of existing plasminogen activators as well as finding new ones. Much of this effort has concentrated on targeting the plasminogen activators to the fibrin that forms the scaffold of a thrombus and to improve the

pharmacokinetics of the activators when administered into the blood stream. This would allow their administration as bolus doses rather than as a continuous delivery that prolongs exposure of the patient to the active agent, and the accompanying risk of undesirable systemic hemorrhage.

5 Based on the results of Phase II clinical trials with targeted plasminogen activators such as TNK-tPA, vampire bat salivary plasminogen activator, however, the anticipated improvement in safety profiles of the new plasminogen activators have not been realized clinically following thrombolytic therapy. The percentage of moderate and major bleeding episodes, including intracranial hemorrhage and stroke, 10 were comparable with the original unmodified tPA. The clogged arteries were not opened earlier, and the rate of re-occlusions remained unchanged. It appeared that the only benefit these activators have is the prolonged plasma half-life and the possibility of bolus administration.

Another problem with plasminogen activators is that they have limited 15 efficacy in the treatment of long clots found in peripheral arterial occlusions (PAO). These thrombi are typically aged and can grow to a significant size. The average size of peripheral thrombi found both in the native arteries and grafts is 31 ± 11 cm. Aged and retracted thrombi are deficient in plasminogen, which therefore limits the susceptibility of old thrombi to plasminogen activator-induced thrombolysis. It is 20 quite common for a patient with a PAO to be treated for 24 hours or more with urokinase and even after this prolonged period not to have complete patency of the vessel. The problem is greater with the delivery of the existing thrombolytic agents via catheter directly into the interior of the thrombus where there are reduced levels of the plasminogen substrate.

A fundamentally different approach to avoid the problems associated with the systemic administration of a plasminogen activator to generate sufficient plasmin at the site of the thrombus, is to administer plasmin itself directly to the patient. This is because plasmin is ultimately the enzyme mediating thrombolysis initiated by 5 plasminogen activators. Direct delivery of active plasmin directly into retracted thrombi would circumvent the inherent plasminogen deficiency of these thrombi and provide predictable, rapid and effective thrombolysis irrespective of plasminogen content.

Reich et al. in US Patent No:5,288,489 discloses a fibrinolytic treatment that 10 includes parenteral administration of plasmin into the body of a patient. The concentration and time of treatment were sufficient to allow active plasmin to attain a concentration at the site of an intravascular thrombus that is sufficient to lyse the thrombus or to reduce circulating fibrinogen levels. *Reich et al.*, however, require generation of the plasmin from plasminogen immediately prior to its introduction into 15 the body.

In contrast, *Jenson* in U.S. Patent No. 3,950,513 discloses a porcine plasmin preparation that is asserted to be stabilized at low pH. The plasmin solution is neutralized before systemic administration to humans for thrombolytic therapy.

Yago et al. in U.S. Patent No. 5,879,923 discloses plasmin compositions 20 useful as a diagnostic reagent. The compositions of *Yago et al.* consist of low concentrations of plasmin at a neutral pH and an additional component that may be 1) an oligopeptide comprising at least two amino acids, or 2) at least two amino acids, or 3) a single amino acid and a polyhydric alcohol.

Plasmin represents a second mechanistic class of thrombolytic agents, distinct

from the class of plasminogen activators. Although plasmin had been investigated as a potential thrombolytic agent, numerous technical difficulties have prevented effective clinical use of this fibrinolytic enzyme. These difficulties included the challenge of preparing pure plasmin that is free of all functional traces of the 5 plasminogen activator used to generate plasmin from the inactive precursor, plasminogen. The thrombolytic activity of these earlier plasmin preparations was eventually attributed to the presence of contaminating plasminogen activators rather than to plasmin itself. The contaminating plasminogen activators, however, also triggered systemic bleeding at sites other than at the targeted thrombus. An additional 10 drawback of streptokinase used for plasmin preparations is that its presence in a preparation of plasmin often causes adverse immune responses including fever and anaphylactic shock.

The most important limitation to the clinical use of plasmin is that, as a serine protease with broad specificity, it is highly prone to autodegradation and loss of 15 activity at physiological pH. This provides severe challenges to the production of high-quality stable plasmin formulation suitable for prolonged periods of storage prior to use, and to safe and effective administration of plasmin to human patients suffering from occlusive thrombi.

What is needed, therefore, is a method of administering a stable form of active 20 plasmin that is substantially free of plasminogen activators and which is active upon encountering a targeted vascular thrombotic occlusion.

What is also needed is a method of lysis of thrombi that directly delivers an activatable form of active plasmin via a catheter into the interior of the thrombus.

What is further needed is a method of thrombolysis in which an administered thrombolytic agent is restricted to the thrombotic site and which exhibits reduced systemic, and especially intracranial, hemorrhage.

These and other objectives and advantages of the invention will become fully 5 apparent from the description and claims that follow or may be learned by the practice of the invention.

Summary of the Invention

This invention relates to the discovery that thrombolytic therapy can be 10 improved by the administration of reversibly inactivated acidified plasmin directly into, or proximal to, a thrombus. Purified plasmin is unstable at physiological pH due to autodegradation and, therefore, plasmin has not been readily available for therapeutic administration. The present invention provides a method of administering a therapeutic dose of a fibrinolytic composition to a human or animal having a 15 vascular thrombotic occlusion, comprising administering a therapeutic dose of a pharmaceutically acceptable reversibly inactivated acidified fibrinolytic composition substantially free of plasminogen activator. The present invention further provides a method of administering a therapeutic dose of an reversibly inactivated acidified fibrinolytic composition comprising plasmin and a pharmaceutically acceptable 20 acidified carrier, wherein the pharmaceutically acceptable carrier has a low buffering capacity.

The present invention also provides a method of administering a therapeutic dose of a reversibly inactivated acidified fibrinolytic composition, wherein the fibrinolytic composition comprises plasmin and a pharmaceutically acceptable

acidified carrier, wherein the pharmaceutically acceptable acidified carrier comprises water and a pharmaceutically acceptable acid selected from the acid forms of carboxylic acids, amino acids or other compounds having a low buffering capacity and the acidified carrier has a pH less than about 4.0.

5 The present invention provides a method of administering a therapeutic dose of a reversibly inactivated acidified plasmin and a pharmaceutically acceptable acidified carrier, further comprising a pharmaceutically acceptable stabilizer such as, but not limited to, a sugar or a polyhydric alcohol.

In one aspect of the present invention, the fibrinolytic composition comprises
10 a reversibly inactivated acidified serine protease substantially free of its respective activator, a low buffering capacity buffer, and optionally, a stabilizing agent. Such serine proteases include trypsin, chymotrypsin, pancreatic elastase II, cathepsin G, prostate-specific antigen, leukocyte elastase, chymase, tryptase, acrosin, human tissue kallikrein, and plasmin. Plasmin includes Glu-plasmin, Lys-plasmin, derivatives and
15 modified or truncated variants thereof, including, but not limited to, midi-plasmin, mini-plasmin, or micro-plasmin.

The methods of the present invention comprise acidic conditions and stabilizers that render the plasmin stable for storage. The plasmin used in the present invention is obtained by activating plasminogen, and is isolated and stored in an
20 acidified solution having a pH of less than about 4 to provide a stable formulation of plasmin. The fibrinolytic composition of the present invention may be lyophilised and is substantially free of plasminogen activator. The low buffering capacity of the plasmin composition allows rapid titration to a physiological pH when administered to a thrombus or serum. Acidified plasmin is rapidly neutralized and activated when

administered in a low buffering capacity solution directly to the clot site for thrombolytic therapy.

Additional objects, features, and advantages of the invention will become more apparent upon review of the detailed description set forth below when taken in conjunction with the accompanying drawing figures, which are briefly described as follows.

Brief Description of the Figures

10 Fig. 1 illustrates the pH dependence of plasmin activity as measured with the chromogenic substrate S2251.

15 Fig. 2 illustrates plasmin stability in acidified water (pH 3.7) as measured by a caseinolytic assay.

15 Fig. 3 illustrates fibrin thrombolysis by plasmin in PBS.

20 Fig. 4 illustrates the effectiveness of plasmin or tPA plus plasminogen in thrombolysis.

20 Fig. 5 illustrates thrombolytic potency of active plasmin.

25 Fig. 6 illustrates the effect of plasma inhibitors on plasmin-induced thrombolysis.

25 Fig. 7 compares local administration of tPA or Lys-plasmin on blood flow restoration, and FVIII and fibrinogen consumption, at 60 minutes.

30 Fig. 8 compares local administration of tPA or Lys-plasmin on blood flow restoration at 90 minutes, and FVIII and fibrinogen consumption at 60 minutes.

Fig. 9 illustrates the effect of local administration of tPA versus plasmin on cuticle bleed times.

35 Fig. 10 illustrates lysis of retracted blood clots with equimolar amount of reversibly inactivated acidified plasmin or mini-plasmin.

Fig. 11 compares local administration of tPA and plasmin on thrombus lysis,

and Factor VIII and fibrinogen consumption, at 60 minutes.

Fig. 12 compares local administration of tPA and plasmin on thrombus lysis at 90 minutes, and Factor VIII and fibrinogen consumption at 60 minutes.

5

Fig. 13 illustrates the risk/benefit evaluation of plasmin versus tPA.

Fig. 14 illustrates the progressive degradation of a plasmin composition at a pH of 2.2, 3.5, or 3.7.

10

Fig. 15 illustrates the cleavage sites generated in plasmin at pH 2.2 and 3.8.

Fig. 16 illustrates the stability at 37° C of a reversibly inactivated acidified plasmin at pH of 3.7, with carbohydrate stabilizers.

15

Fig. 17 illustrates the stability at 37°C of a reversibly inactivated acidified plasmin at a pH of 3.7 with glucosamine, niacinamide, thiamine or citrulline as a stabilizing agent.

20

Fig. 18 illustrates the titration, with human serum, of plasmin solutions having various low buffering capacity buffers.

Detailed Description of the Invention

25

A full and enabling disclosure of the present invention, including the best mode known to the inventors of carrying out the invention, is set forth more particularly in the remainder of the specification, including reference to the Examples. This description is made for the purpose of illustrating the general principles of the invention and should not be taken in the limiting sense.

The present invention addresses the need for a method of thrombolysis that allows the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a thrombotic occlusion. The invention provides a method for administering a therapeutic dose of a fibrinolytic

composition to a human or animal having a thrombotic occlusion, comprising administering parenterally to the human or animal a therapeutic dose of a pharmaceutically acceptable reversibly inactivated acidified fibrinolytic composition substantially free of plasminogen activator, allowing the administered fibrinolytic

5 composition to interact with the thrombotic occlusion, monitoring the level of vascular flow of the human or animal, and repeating these steps until a pre-selected level of vascular flow is attained. The method of the invention further provides for the use of a fibrinolytic composition comprising an reversibly inactivated acidified plasmin substantially free of plasminogen activator in a low buffering capacity buffer.

10 The method also provides for the intravascular catheter direct delivery of the fibrinolytic composition into or in the immediate vicinity of the thrombus, thereby minimizing the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.

With the escalating use of arterial and venous catheters in the clinics, local

15 delivery of reversibly inactivated acidified plasmin in close proximity to, or actually into, a thrombus offers an attractive therapeutic opportunity for thrombolysis. Being an active serine protease, plasmin is a direct thrombus dissolving agent, in contrast to plasminogen activators that require the presence of the zymogen plasminogen in the vicinity of the thrombus. Local catheter-directed thrombolytic therapy with active

20 plasmin can be regulated to achieve localized total thrombolysis, and plasmin has the potential to be a safer thrombolytic agent because the lower dosage required for local delivery may significantly reduce bleeding complications frequently associated with high dose thrombolytic therapy induced by plasminogen activators. Any spillage of plasmin from the immediate vicinity of the thrombus site will be rapidly neutralized

by circulating α_2 -antiplasmin.

There are several technical challenges associated with plasmin purification, and storage, as well as with its therapeutic use and delivery. Plasmin is an active serine protease and is subject to autodigestion and inactivation at physiological pH.

5 Plasmin degradation, unfortunately, is also most evident in the pH range required for *in vivo* thrombolysis.

The fibrinolytic composition, as incorporated into the present invention, includes the maintenance of the plasmin in an acidic buffer during purification, as well as its formulation in an acidified carrier having a pharmaceutically acceptable 10 low buffering capacity buffer, thereby providing a reversibly inactivated acidified plasmin-containing fibrinolytic composition substantially free of plasminogen activator. It is contemplated to be within the scope of the present invention for the fibrinolytic composition to be a lyophilized composition that may be reconstituted by the addition of a pharmaceutically acceptable carrier such as, but not limited to, water, 15 physiological saline or any other solvent that will allow administration of the composition to a human or animal. Its efficacy in restoring vascular patency was demonstrated in *in vitro* assays and in an *in vivo* rabbit jugular vein thrombolysis model.

The term "reversibly inactivated" as used herein refers to an enzymic activity 20 that is substantially free of activity under a specific set of conditions but will revert to an active form when transferred to another set of conditions.

The term "pharmaceutically acceptable carrier" as used herein refers to any carrier that is physiologically tolerated by a recipient human or animal, including, but not limited to, water, salt solutions, physiological saline, or any other liquid or gel in

which a fibrinolytic agent such as plasmin may be dissolved or suspended. The “pharmaceutically acceptable carrier” may include any pharmaceutically acceptable compound that will give a plasmin solution having a pH below about 4.0 and which has low or zero buffering capacity.

5 The term “low buffering capacity buffer” as used herein refers to the amount of acid or base that a buffer can neutralize before the pH begins to change to an appreciable degree. As used herein a low buffering capacity buffer will be significantly pH adjusted by the addition of a small volume of an acid or base relative to the volume of the low buffering capacity buffer solution. This term is meant to
10 include solutions acidified by strong acids including, but not limited to, hydrochloric acid, nitric acid or sulfuric acid, and which have no buffering capacity.

The term “physiological pH” as used herein refers to a pH between about pH 6.5 and 7.5, more typically between pH 7.1 to 7.5.

15 The term “thrombus” as used herein refers to a thrombus in a blood vessel or a device contacting blood (e.g. catheter devices or shunts). A thrombus may comprise fibrin and may further comprise, but is not limited to, platelets, erythrocytes, lymphocytes, lipid, serum constituents or any combination thereof. A “thrombus” may be, but is not limited to, an annular thrombus, ball thrombus, hyaline thrombus, mural thrombus, stratified thrombus or white thrombus.

20 The term “thrombotic occlusion” as used herein refers to a partial or total blockage of a vessel due to the formation of a thrombotic clot, wherein the thrombus comprises at least fibrin. The vascular vessel occluded may be, but is not limited to, a vein, artery, venule, arteriole, capillary, vascular bed or the heart and may be within any vascularized organ or tissue of the human or animal body. The thrombotic

occlusion may also be of a catheter or other implant, including, but not limited to, prosthetic vessels and grafts of synthetic, human or animal origin, effectively blocked by an occlusion comprising fibrin.

The term "catheter device" as used herein refers to any catheter or tube-like 5 device that may enter the body, and includes but is not limited to, an arterial catheter, cardiac catheter, central catheter, central venous catheter, intravenous catheter, balloon catheter devices peripherally inserted central catheter, pulmonary artery catheter or tunneled central venous catheter and arterio-venal shunts.

The term "pharmaceutically acceptable acidified carrier" as used herein refers 10 to any pharmaceutically acceptable carrier that has been acidified to a pH below about 4.0. The "pharmaceutically acceptable acidified carrier" may comprise a low or zero buffering capacity buffer such as a carboxylic acid such as, but not limited to, formic, acetic, propionic, butyric, citric, succinic, lactic or malic acids acidified to a pH below about 4.0 by the addition of an inorganic acid; or at least one amino acid such 15 as, but not limited to, glycine, alanine, valine, isoleucine, threonine or glutamine, or at least one inorganic acid such as, but not limited to, sulfuric acid, hydrochloric acid, nitric acid or phosphoric acid or any combination thereof. It is contemplated to be within the scope of the present invention for the acid moiety of the pharmaceutical carrier to be at least one physiologically tolerated buffer, oligopeptide, inorganic or 20 organic ion or any combination thereof that will maintain a pH in the pharmaceutically acceptable carrier below a value of about 4.0.

The term "carbohydrate" as used herein refers to any pharmaceutically acceptable saccharide or disaccharide such as, but not limited to, glucose, fructose, maltose or mannose, sugar alcohols including, but not limited to, sorbitol and

mannitol, and polysaccharides such as, but not limited to, dextrans, dextrins, glycogen, starches and celluloses, or any combination or derivative thereof that are pharmaceutically acceptable to a human or animal.

The term "stabilizing agent" as used herein refers to at least one compound 5 such as, but not limited to, glycerol, ascorbate, niacinamide, glucosamine, thiamine or inorganic salt such as, but not limited to, sodium chloride, potassium chloride, magnesium chloride or manganese chloride or any combination thereof that will increase the stability of a preparation of plasmin.

The term "reversibly inactivated acidified plasmin" as used herein refers to 10 any catalytically active form of plasmin capable of proteolytically cleaving fibrin when under physiological conditions, but reversibly inactivated when placed at a pH between about pH 2.5 to about 4.0. The term "inactivated" as used herein refers to a total or substantial reduction in enzymatic activity compared to the activity at physiological pH. The term "active plasmin" as used herein refers to a plasmin under 15 conditions where the plasmin is capable of proteolytically cleaving fibrin. The term "plasmin" includes, but is not limited to Glu-plasmin, Lys-plasmin, derivatives, modified or truncated variants thereof. The term "truncated variants" includes, but is not limited to, the midi-plasmin, mini-plasmin or micro-plasmin as disclosed in U.S. Patent No. 4,774,087 incorporated herein by reference in its entirety.

20 The term "anti-coagulant" as used herein refers to any compound capable of inhibiting the formation of a thrombus including, but not limited to, hirudin, heparin, thrombin inhibitors, platelet inhibitors, platelet aggregation inhibitors and any derivatives or combinations thereof.

The term "serine protease" as used herein refers to any serine protease capable

of proteolytically cleaving fibrin including, but not limited to, plasmin, trypsin, chymotrypsin, pancreatic elastase II, cathepsin G, prostate-specific antigen, leukocyte elastase, chymase, tryptase, acrosin and human tissue kallikrein.

One limitation of current thrombolytic therapy with plasminogen activators is
5 plasminogen availability surrounding or within a thrombus. The local delivery of a fibrinolytic agent to a thrombus now allows plasmin itself to be a potent therapeutic agent directly administered to a thrombus. In contrast to various plasminogen activators that are currently used as thrombolytics, direct localized thrombolytic therapy with plasmin can be intensified to whatever level is required to achieve clot
10 lysis. This is because plasmin acts directly upon the fibrin polymer. Also, plasmin, when delivered directly into or adjacent to a thrombus, allows a lower effective dose to be administered with a concomittant reduction in the systemic hemorrhage typically associated with conventional thrombolytic therapy. Excess plasmin can also be rapidly inactivated by circulating α_2 -antiplasmin.

15 Highly purified active plasmin of the present invention was therefore prepared from plasminogen that had been purified from Cohn Fraction II + III. The purity of plasmin was greater than 95% and specific activity was in the range of 18-23 CU/mg. The plasmin preparations were substantially free of urokinase, or any other plasminogen activator, that had been used for the conversion of plasminogen into
20 plasmin. The present invention also contemplates that plasmin substantially free of plasminogen activator may be prepared from any source including, but not limited to, mammalian serum, a recombinant plasminogen or a truncated plasminogen such as, but not limited to, the mini-plasminogen or micro-plasminogen as disclosed by *Wu et al.* in U.S. Patent No. 4,774,087, incorporated herein by reference in its entirety.

The plasmin of the present invention was purified to substantially remove plasminogen activators by binding to a benzimidine-Sepharose chromatography column and eluted plasmin was collected and stored in an acidified pharmaceutically acceptable carrier having a low buffering capacity buffer. A low pH in the range of 5 about 2.5 to about 4.0 significantly stabilized the plasmin, even when held at room temperature or greater. While not bound by any one theory, it is believed that at this low pH value the plasmin no longer has serine protease activity that would otherwise lead to autodegradation of the plasmin, as would be seen when plasmin is to be stored at the physiological pH of about 7.0 - 7.5.

10 When the reversibly inactivated acidified plasmin is administered, according to the methods of the present invention, directly into a thrombus or proximal thereto, the reversibly inactivated acidified plasmin in the low or zero buffering capacity buffer encounters the serum buffering capacity at the physiological pH of about 7.4. The low buffering capacity of the pharmaceutically acceptable carrier is neutralized, 15 whereupon the plasmin reverts to its active state and proteolytically digests the fibrin of the thrombus.

By initially employing a method of plasmin preparation that renders plasmin proteolytically inactive until administered into, or immediately adjacent to, a thrombus, and which is also substantially free of any plasminogen activator, the 20 likelihood of inducing undesirable systemic hemorrhage is diminished. Excess administered plasmin is rapidly inactivated by circulating serum inhibitors such as α_2 -antiplasmin, and the relatively stable plasminogen activators that would otherwise circulate to induce distal fibrinolysis are substantially absent.

Acidified plasmin may be readily stored in pharmaceutically acceptable

carriers having a low or zero buffering capacity such as, but not limited to, aqueous 5 mM glycine. Any pharmaceutically acceptable ion may be used, singularly or in combination, if a pH is in the range of about 2.5 – 4.0. Typically, reversibly inactivated acidified plasmin has been maintained at a pH of 3.1 – 3.5. The 5 pharmaceutically acceptable acidic ions incorporated in the carrier to maintain a low pH may be selected from oligopeptides, at least one amino acid, or organic or inorganic acids or a combination thereof. Stabilization may be further enhanced by the inclusion of at least one pharmaceutically acceptable compound that may be, but is not limited to a carbohydrate.

10 A description of the method of treating a thrombotic occlusion in a patient using a therapeutically effective dose of the low-pH plasmin compositions of the present invention is disclosed in U.S. Patent Application Serial No. _____, entitled “Reversibly Inactivated Acidified Plasmin”, commonly assigned and filed contemporaneously with the instant application, and is 15 incorporated herein by reference in its entirety.

Additionally, a process for producing the reversibly inactivated acidified plasmin composition of the instant invention is disclosed in U.S. Patent Application Serial No. _____, entitled “Process for the Production of a Reversible Inactivated Plasmin Composition”, commonly assigned and filed 20 contemporaneously with the instant application, and is incorporated herein by reference in its entirety.

The administration of the plasmin composition can be by any method that will deliver the plasmin as a bolus or as a prolonged infusion directly into a thrombus, or to a site only a short distance proximal to the thrombus, whereupon it can rapidly

encounter the thrombus. By minimizing this distance to the thrombus or by directly administering into the clots, plasmin exposure to plasmin inhibitors in the serum lying between the delivery needle or catheter and the thrombus is reduced. The present invention contemplates that the reversibly inactivated acidified plasmin may be 5 delivered to the thrombus by a catheter. The present invention further contemplates that a cannulated needle, such as, but not limited to a syringe needle, may be used to inject the reversibly inactivated acidified plasmin into a thrombus. It is, however, within the scope of the present invention for any means known to one of skill in the art, to locally administer a fluid to a specific location in a human or animal. Catheter 10 delivery to a vascular or coronary thrombus further allows precision in placing the plasmin, especially within the thrombus. While the present invention provides methods of localized delivery of an reversibly inactivated acidified plasmin in a low buffering capacity buffer to a thrombus, it is within the scope of the present invention for delivery of the reversibly inactivated acidified plasmin composition thereof to a 15 fibrin occlusion of a catheter implanted in a human or animal.

Using an *in vitro* ¹²⁵I-fibrin-labeled thrombolysis assay, it was shown that plasmin was capable of dissolving thrombi in a dose-dependent manner. Fibrinolysis was enhanced by deletion of either α_2 -antiplasmin or α_2 -microglobulin in plasma surrounding the thrombus, as well as by the deletion of all inhibitors (i.e., in PBS). 20 These results show that thrombolysis by plasmin is under very strict regulation by the endogenous plasmin inhibitors, and provides the basis for safer thrombolytic therapy.

The *in vivo* efficacy of reversibly inactivated acidified plasmin (1-3 mg/kg) in a low buffering capacity buffer directly administered locally to a thrombus via a catheter was compared with that of tPA (0.5 and 1.0 mg/kg) in the rabbit jugular vein

thrombosis model. The rate of thrombolysis was monitored. In addition, the consumption of Factor VIII and fibrinogen, as well as cuticle bleeding time (CBT), were measured as indicators of the systemic lytic state. In comparison with 0.5 mg/kg of tPA, plasmin provided comparable or significantly better thrombolysis, with 5 comparable consumption of Factor VIII and fibrinogen and similar CBT at 1 mg/kg dose. There was a significantly increased consumption and CBT with plasmin at 3 mg/kg. When compared with 1 mg/kg of tPA, both plasmin and tPA provided very similar thrombolysis rates with significantly less consumption of fibrinogen at 3 mg/kg plasmin.

10 Thus, reversibly inactivated acidified plasmin can be effectively and safely stored and used as a thrombolytic agent during catheter-assisted local thrombolysis without neutralization before administration to a human or animal. Plasmin has comparable, if not superior, fibrinolytic activity compared to tPA, and the safety profile appears at least similar in this animal model of local thrombolytic delivery.

15 It is contemplated to be within the scope of the present invention that the reversibly inactivated acidified fibrinolytic enzyme may be, but is not limited to, plasmin, derivatives of plasmin such as truncated forms thereof including, but not limited to, mini-plasmin and micro-plasmin.

 The present invention provides a method of administering a therapeutic dose 20 of a fluid fibrinolytic composition preparation substantially free of plasminogen activators to the immediate vicinity of, or directly into, a thrombotic occlusion of a vascular vessel or an occluded catheter device. The invention further provides a method for delivering a therapeutic dose of a fluid reversibly inactivated acidified plasmin composition to a vascular thrombotic occlusion wherein the plasmin may be

stabilized prior to administration at a pH of about 4.0. The present invention further provides a method for delivering a therapeutic dose of a fluid reversibly inactivated acidified plasmin in a low buffering capacity buffer directly into a vascular thrombotic occlusion, or thrombus, whereupon the plasmin composition reverts to a 5 physiological pH that allows the plasmin to proteolytically cleave fibrin.

In one embodiment of the present invention, the method of the invention comprises the steps of identifying a human or animal having a thrombotic occlusion, administering to the human or animal a therapeutic dose of a pharmaceutically acceptable reversibly inactivated acidified fibrinolytic composition in a low buffering capacity buffer, allowing the administered fibrinolytic composition to interact with the vascular occlusion, monitoring the level of vascular flow of the human or animal; and repeating steps of administering the fibrinolytic composition until a pre-selected 10 level of vascular flow is attained.

In another embodiment of the present invention, the reversibly inactivated 15 acidified fibrinolytic composition comprises plasmin and a pharmaceutically acceptable acidified carrier having a low buffering capacity buffer.

In still another embodiment of the present invention, the pharmaceutically acceptable acidified carrier comprises water and at least one pharmaceutically acceptable acid, wherein the acid is an organic acid, which may be, but is not limited 20 to, a carboxylic acid, an oligopeptide, an amino acid, or an inorganic acid and having a low or zero buffering capacity, and the acidified carrier has a pH less than about 4.0.

In yet another embodiment, the pharmaceutically acceptable acidified carrier comprises water and a pharmaceutically acceptable acid selected from the acid forms of formate, acetate, citrate, glycine, isoleucine, serine, threonine, glutamine, and

alanine, wherein the acidified carrier has a pH less than about 4.0.

In a further embodiment, the pharmaceutically acceptable acid is the acid form of acetate or citrate.

In yet another embodiment, the pharmaceutically acceptable acid is the acid 5 form of acetate.

In an embodiment of the method of the present invention, the reversibly inactivated acidified fibrinolytic composition has a pH of between about 2.5 and about 4.0. In another embodiment of the method of the present invention, the fibrinolytic composition has a pH of about 3.7.

10 In other embodiments of the method of the present invention, the plasmin is in the concentration range of between about 0.01 mg/ml to about 50 mg/ml. In one embodiment of the method of the present invention the plasmin is in the concentration range of between about 0.1 mg/ml to about 10 mg/ml.

15 In further embodiments of the method of the present invention, the acidic ion is in the concentration range of between about 1 mM to about 500 mM. In one embodiment of the method of the present invention, the acidic ion is in the concentration range of between about 1 mM and 50 mM.

20 Embodiments for practicing the method of the present invention further comprise a physiologically acceptable plasmin stabilizer, wherein the carbohydrate is selected from glucose, maltose, mannitol, sorbitol, sucrose, lactose or trehalose, wherein the sugar has a concentration in the range of about 0.2% w/v to about 20% w/v. In one embodiment, the sugar is glucose and the concentration thereof is about 20%.

Embodiments of the method of the present invention further comprise the

therapeutic dose of the reversibly inactivated acidified plasmin in the range of between about 0.01 mg plasmin/kg body weight and 10 mg plasmin/kg body weight.

In embodiments of the method of the present invention, the reversibly inactivated acidified fibrinolytic composition is administered intravascularly or 5 intrathrombus. In one embodiment of the method of the present invention, the reversibly inactivated acidified plasmin in a low pH-buffered capacity buffer is administered directly into, or proximally to a thrombus by an intravascular catheter device. In still another embodiment of the method of the present invention, the intravascular catheter is directed to a vascular occlusion.

10 Even though the invention has been described with a certain degree of particularity, it is evident that many alternatives, modifications, and variations will be apparent to those skilled in the art in light of the present disclosure. Accordingly, it is intended that all such alternatives, modifications, and variations that fall within the spirit and the scope of the invention be embraced by the defined claims.

15 The following examples are presented to describe preferred embodiments and utilities of the present invention, but should not be construed as limiting thereof.

It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to 20 constitute preferred modes for its practice. Those of skill in the art, in light of the present disclosure, will appreciate that many changes can be made in the specific embodiments disclosed and still obtain like or similar results without departing, again, from the spirit and scope of the present invention.

Example 1: Sources of proteins investigated.

Plasminogen was purified from Cohn Fraction II + III paste by affinity chromatography on Lys-Sepharose as described by *Deutsch & Mertz* (1970). Thus, 200 g of the paste was resuspended in 2 liter of 0.15M sodium citrate buffer, pH 7.8.

5 The suspension was incubated overnight at 37°C, centrifuged at 14,000 rpm, filtered through fiberglass and mixed with 500 ml of Lys-Sepharose 4B (Pharmacia). Binding of plasminogen was at room temperature for 2 hours. The Lys-Sepharose was then transferred onto a 2-liter glass filter, and washed several times with 0.15M sodium citrate containing 0.3M NaCl until the absorbance at 280 nm dropped below 0.05.

10 Bound plasminogen was eluted with three 200-ml portions of 0.2M ϵ -aminocaproic acid. Eluted plasminogen was precipitated with 0.4 g solid ammonium sulfate/ml of plasminogen solution. The precipitate of crude (80-85% pure) plasminogen was stored at 4°C.

Low-molecular weight urokinase (LMW-urokinase) (Abbokinase-Abbott Laboratories, Chicago III.) was further purified by affinity chromatography on benzamidine-Sepharose. The urokinase was then coupled to CNBr-activated Sepharose 4B by mixing 1.3 mg of LMW-urokinase in 50 mM acetate buffer, pH 4.5, and diluting with 5 ml of the coupling buffer, 0.1M sodium bicarbonate, pH 8.0.

This solution was immediately combined with 5 ml of CNBr-activated Sepharose previously swollen and washed in 0.1M HCl. The coupling occurred for 4 hours on ice with shaking. The excess of the CNBr active group was blocked with 0.1M Tris, pH 8.0. Each batch of urokinase-Sepharose was used 5 times and stored in 50% glycerol in water at 4°C between the cycles. Tissue plasminogen activator (ACTIVASETM) was from Genentech. Plasminogen-free fibrinogen and α -thrombin

(3793 U/ml) were from Enzyme Research, Inc. α_2 -Antiplasmin was obtained from Athens Research Technologies. Commercially available plasmin was from Haemotologic Technologies, Inc. Chromogenic plasmin substrate S2251 was from Chromogenix. 125 I-Labeled human fibrinogen (150-250 μ Ci/mg) was from Amersham

5 Pharmacia Biotech. SDS-polyacrylamide gel electrophoresis was performed in the Pharmacia Phast System apparatus using pre-made 8-25% gradient gels and SDS-buffer strips.

Example 2: Purification of active plasmin

10 (i) *Activation of plasminogen to plasmin using urokinase-Sepharose.*

Plasminogen was cleaved to plasmin yielding plasmin without contamination of the final preparation by using an immobilized plasminogen activator. Urokinase cleaves plasminogen directly. Plasminogen activation by urokinase does not depend on the presence of fibrin as in the case of tPA, and urokinase is a human protein.

15 These factors, and its relative low cost, make urokinase the preferred activator, although this does not preclude the use of tPA, streptokinase or any other cleavage means yielding an active plasmin capable of fibrin degradation. The ammonium sulfate precipitate of crude plasminogen was centrifuged at 14,000 rpm and resuspended in a minimal volume using 40 mM Tris, containing 10 mM lysine, 80

20 mM NaCl at pH 9.0 to achieve the final protein concentration of 10-15 mg/ml. The plasminogen solution was dialyzed overnight against the same buffer to remove ammonium sulfate. The dialyzed plasminogen solution (10-20 ml) was diluted with an equal volume of 100% glycerol and combined with 5 ml of urokinase-Sepharose.

The use of 50% glycerol reduces autodegradation of plasmin formed during

activation. Plasmin is stable in 50% glycerol and can be stored in this solution at – 20°C for an extended period.

The plasminogen activation occurred at room temperature for between 2 hours and 24 hours depending on the freshness of the urokinase-Sepharose. With a fresh 5 batch of urokinase-Sepharose, activation could be completed in 2 hours. It deteriorates, however, and becomes less efficient after several cycles, necessitating the use of SDS-PAGE under reducing conditions to monitor the progress of plasminogen activation. Upon completion of the activation, the plasmin solution was filtered from the urokinase-Sepharose with a glass filter, and immediately applied to 10 benzamidine-Sepharose.

(ii) Capturing of plasmin on benzamidine-Sepharose.

Since the plasmin is a serine protease with trypsin-like specificity, benzamidine-Sepharose is an affinity absorbent that allowed capture of the active plasmin. A plasminogen solution in 50% glycerol was applied to the 50 ml 15 benzamidine-Sepharose column equilibrated with 0.05M Tris, pH 8.0, containing 0.5M NaCl with a flow rate of 3 ml/min. The column was run at 3 ml/min at 3 - 7°C. The front portion of the non-bound peak contained high-molecular weight impurities. The rest of the non-bound peak is represented by residual non-activated plasminogen 20 and by inactive autodegradation products of plasmin.

(iii) Elution of the bound plasmin with low-pH buffer.

To protect plasmin from inactivation at neutral pH conditions, acidic elution conditions were selected. The plasmin bound to benzamidine-Sepharose was eluted with 0.2M glycine buffer, pH 3.0 containing 0.5M NaCl. The bound peak was typically divided into three pools, two front peaks, B1 and B2, and the bulk of the

eluted material as B3.

Non-reducing gel analysis showed that all three pools contained highly pure (>95%) plasmin. The gel analysis, however, in addition to the heavy and light chains of plasmin, revealed some low molecular weight bands in a range of 10-15 kDa as a 5 result of partial internal cleavage degradation of the plasmin.

The front portion of peak B1 typically contained most of the low molecular weight impurities. The B2 and B3 pools were less degraded. The front portion of the bound peak had very little of the plasmin activity and was usually discarded. The loss of activity in this material may be due to autodegradation during chromatography, 10 because there is no glycerol present in the eluted material, and the pH of the front portion is intermediate between the pH of the equilibrating and eluting buffers, typically in a range of pH 6-6.5. The eluted plasmin, substantially free of plasminogen activators, was collected in tubes containing 2M glycine buffer, pH 3.0 (10% of the collected volume).

15 (iv) *Formulation of eluted material in acidified water (pH 3.7).*

Eluted plasmin was dialyzed against water that had been acidified to about pH 3.7 with glacial acetic acid, or against water containing 0.15M NaCl also acidified to about pH 3.7 with glacial acetic acid.

Any acid providing a pharmaceutically acceptable acidified carrier having a 20 low buffering capacity buffer and having a pH between about 2.5 to about 4.0 can be used. For example, also contemplated within the scope of this invention is the use of other acids and amino acids such as, but not limited to, inorganic acids, carboxylic acids, aliphatic acids and amino acids including, but not limited to, formic acid, acetic acid, citric acid, lactic acid, malic acid, tartaric acid, benzoic acid, serine, threonine,

valine, glycine, glutamine, isoleucine, β -alanine and derivatives thereof, either singly or any combination thereof, that will maintain the pH in the pharmaceutically acceptable carrier of about 2.5 to about 4.0.

Plasmin is extremely stable in acidified water and can be effectively used in 5 this form for *in vitro* and *in vivo* studies. Plasmin specific activity was measured using an adapted caseinolytic assay as described by *Robbins & Summaria (1970)*. One ml of 4% casein solution in acidified water and an appropriate volume of 67 mM sodium phosphate buffer, pH 7.4 was added to a test polycarbonate tube. The solutions were vortexed and incubated at 37°C for 10 minutes. Plasmin samples or 10 buffer (blank) were added to each tube at 15-second intervals, mixed thoroughly and incubated at 37°C for 30 minutes. The reaction was stopped with the addition of 3 ml of 15% trichloroacetic acid and the precipitate was allowed to form for 15 minutes. The tubes were centrifuged at 3200 rpm for 20 minutes. The supernatants were transferred to cuvettes and the A_{280} of each sample was determined. The specific 15 caseinolytic activity of each sample was determined by the following formula:

$$\frac{3.27 \times [A_{280} (\text{Plasmin Sample}) - A_{280} (\text{Blank})]}{\mu\text{g Plasmin in Assay}} = \text{caseinolytic units (CU)/mg protein}$$

The plasmin concentration was determined spectrophotometrically using the extinction coefficient of 1.7 for 0.1% solution.

20

Example 3: pH-dependent stability of plasmin

Plasmin exhibits a bell-shaped pH dependence of its catalytic activity. As shown in Fig. 1, plasmin has maximum enzyme activity at pH 7.5 - 8.0, and its

activity rapidly decreases at either more alkaline or more acidic pH values. Plasmin is most inactive, and reversibly so, below pH 4.0, due to the protonation of histidine in the catalytic center, as shown by *Robbins & Summaria, (1976)* and *Castellino & Powell (1981)*.

5 Plasmin is very unstable at a physiological pH. Both the heavy chain and light chains of plasmin degraded dramatically within hours at room temperature and 4°C. Plasmin was formulated at 1 mg/ml in 0.04M sodium phosphate, pH 7.4, and incubated at 22°C or 4°C for 6 hours. During the incubation, the plasmin integrity was analyzed every two hours by reducing SDS-PAGE analysis. Both the heavy 10 chain and light chain degraded rapidly within hours at 22°C and 4°C as shown in Table 1.

Table 1. The rapid degradation of plasmin in neutral pH solution at 22°C and 4°C.

Plasmin	Buffer	% of intact heavy chain						% of intact light chain			
		pH	Temp	Initial	2hr	4hr	6hr	Initial	2hr	4hr	6hr
1mg/ml	0.04M PO ₄	7.4	22°C	100%	27%	27%	29%	100%	29%	26%	28%
1mg/ml	0.04M PO ₄	7.4	4°C	100%	32%	27%	25%	100%	33%	25%	22%

(The intact heavy chain and light chain of plasmin at initial time point were 15 normalized as 100%).

Plasmin at 1 mg/ml was incubated at 37°C for 14 days under different acidic conditions. The changes in plasmin heavy chain and light chain were analyzed by reducing SDS-PAGE. Plasmin was formulated at 1 mg/ml in 0.04M sodium phosphate, pH 7.4 and was also incubated at 4°C for six hours. During the 20 incubation, the activity of the plasmin sample was measured every two hours by chromogenic potency assay. Plasmin potency was quantitatively measured using the

MLA 1600C analyzer (Pleasantville, NY). Plasmin hydrolyzed the chromogenic substrate S-2403 (D-pyroglutamyl-L-Phenylalanyl-L-Lysine-p-Nitroaniline hydrochloride or abbreviated as pyro-Glu-Phe-Lys-pNA) to form peptide and the chromophoric group p-nitroaniline (pNA). The rate of color formation was measured 5 kinetically at 405 nm. The amount of substrate hydrolyzed was proportional to the plasmin activity in the sample. A standard curve was generated from the linear regression of the rate of color formation (OD/min) versus the potency of a plasmin standard. The linear equation together with the observed rate for an unknown sample was used to calculate the potency of unknowns. The potency of plasmin was reported 10 in units of mg/ml.

Plasmin integrity was significantly decreased by incubation at a physiological pH, as shown in Table 2.

Table 2. The rapid decrease of plasmin activity in neutral pH solution at 4°C.

Plasmin	Buffer	pH	Chromogenic Potency			
			Initial	2hr	4hr	6hr
1mg/ml	PO ₄ , 0.04M	7.4	100%	43.3%	32.6%	26.4%

15 (*The activity of plasmin solution at initial time point was normalized as 100%.)

In this neutral pH solution, plasmin activity decreased more than 70% after 6 hours at 4°C.

Plasmin formulated in acidified water at pH 3.7 is stable. It can be kept in this 20 form for months at reduced temperatures without any loss of activity or the appearance of degradation products of a proteolytic or acidic nature. Fig. 2 and the data of Table 3 show the stability of plasmin at 4°C and at room temperature.

Table 3. Stability of 1 mg/ml plasmin in the following acidic conditions at 37°C.

Formulation	Plasmin (mg/ml)	Acidic Condition	pH	% intact heavy chain after 14 days at 37°C	% intact light chain after 14 days at 37°C
1	1	5mM HAC/NaAc	2.5	19%	62%
2	1	5mM HAC/NaAc	3.0	41%	92%
3	1	5mM HAC/NaAc	3.4	48%	92%
4	1	5mM HAC/NaAc	3.4	49%	96%
5	1	5mM HAC/NaAc	3.4	50%	96%
6	1	5mM HAC/NaAc	3.7	13%	123%
7	1	5mM HAC/NaAc	4.0	9.3%	107%
8	1	5mM citric acid/Na citrate	2.27	9.3%	64%
9	1	5mM citric acid/Na citrate	3.1	33%	68%
10	1	5mM citric acid/Na citrate	3.56	46%	88%
11	1	5mM citric acid/Na citrate	4.0	7.4%	104%
12	1	5mM glycine	2.2	7.3%	104%
13	1	5mM glycine	3.1	36%	70%
14	1	5mM glycine	3.5	49%	85%
15	1	5mM glycine	3.8	12%	85%
16	1	5mM glycine	4.1	6%	81%
17	1	5mM serine	3.4	56%	100%
18	1	5mM threonine	3.4	54%	100%
19	1	5mM valine	3.4	52%	96%
20	1	5mM isoleucine	3.4	51%	100%
21	1	5mM β -alanine	3.7	33%	90%
22	1	2mM benzoic acid	3.5	42%	93%
23	1	2mM lactic acid	3.5	45%	91%
24	1	2mM malic acid	3.5	50%	90%
25	1	2mM tartaric acid	3.5	28%	87%

(The intact heavy chain and light chain in each formulation before incubation were normalized as 100%; HAc/NaAc = acetic acid/sodium acetate)

At 4°C, plasmin is stable for at least nine months. Even at room temperature,

5 reversibly inactivated acidified plasmin is stable for at least two months. Long-term stability at room temperature is important because it would make this formulation compatible with long regimens of thrombolytic administration. For example, 36 hour administration of thrombolytics such as tissue plasminogen activator or urokinase is

common in treatment of peripheral arterial occlusions. Shown in Fig. 3 is a plot of pH versus percent heavy chain relative to total protein in each lane of the SDS gels. The results demonstrate a pH stability optimum of about 3.1-3.5, irrespective of the type of buffer, or buffer concentration.

5 The ability of reversibly inactivated acidified plasmin to become fully active upon transfer to physiological pH is evidenced by its activity in the caseinolytic assay and also in the ¹²⁵I -fibrin-labeled thrombolysis assays. Both of these assays are performed at pH 7.4, and there was complete recovery of plasmin activity during the change of pH and passing through the isoelectric point (pH 5 - 5.5). The plasmin is 10 formulated in a low-buffering capacity solvent and, when added to a buffered solution such as plasma, it rapidly adopts the neutral or physiological pH instantly and the precipitation that usually accompanies the slow passage through the isoelectric point, does not occur.

15 **Example 4: Plasmin has the same intrinsic fibrinolytic potency as a**

plasminogen/plasminogen activator mixture

Plasmin has the same intrinsic fibrinolytic potency as a plasminogen/plasminogen activator mixture. Fibrinolytic potency of plasmin was compared with that of a Lys-plasminogen and tPA mixture. These experiments were 20 performed in a defined system consisting of an ¹²⁵I-radiolabeled fibrin thrombus submersed in PBS. Fig. 4 shows that, in a buffered environment, thrombolysis achieved with plasmin is almost identical to the Lys-plasminogen plus tPA mixture (curves a and b, respectively). At the same time, no thrombolysis was observed with tPA alone (curve c) or in the absence of any proteins (curve d). The data obtained

with tPA alone shows that its activity is dependent on its substrate, plasminogen, to be an effective thrombolytic.

These data indicate that, in the absence of inhibitors and other protein factors present in plasma, there is no difference in the ability to lyse fibrin thrombi between 5 purified plasmin and the combination of tPA and Lys-plasminogen activated with tPA. In order to assess the thrombolytic potency of active plasmin, the ¹²⁵I-fibrin-labeled thrombolysis assay was performed with plasma thrombi in a plasma environment.

10

Example 5: Role of plasmin inhibitors in regulating plasmin activity

¹²⁵I-fibrin labeled thrombolysis assay. The fibrinolytic properties of plasmin were determined in an *in vitro* system consisting of a radio-labeled plasma thrombus immersed in human citrated plasma as described by *Lijnen et al.* (1986). Plasma used in all experiments was single donor plasma thawed at 37°C, aliquoted, re-frozen and 15 stored at -80°C. The stock solution of ¹²⁵I-labeled fibrinogen was prepared by rehydrating the contents of the vial (approximately 110μCi/vial) with 1.0 ml of 0.15M sodium citrate and was stored at 4°C.

Ten μl of ¹²⁵I-fibrinogen was added to a polycarbonate test tube containing 250 μl of plasma at 37°C and mixed briefly. Twenty-five μl of α-thrombin, diluted 20 with 0.1M CaCl₂ to a final concentration of 10-20 μM, was added to the plasma. The radio-labeled thrombi were allowed to age for five minutes at 37°C and then washed with PBS. The thrombi were transferred into test tubes containing 2.25 ml plasma or buffer, one thrombus per tube.

A baseline radioactivity sample was measured for each thrombus. Plasmin

was added to each tube after the addition of each thrombus. The thrombi were returned to 37°C for the duration of the experiment. Further samples were taken at indicated time points for measurement of released radioactivity. The extent of thrombolysis was calculated from the ratio between the amount of radioactivity released from the thrombus into the plasma and the total amount of soluble radioactivity in the reaction tube. The release of labeled fibrin degradation products, expressed in percent, was plotted versus time.

In addition to the plasma milieu, some thrombolysis experiments were conducted in a buffer environment or with plasma lacking α_2 -antiplasmin or α_2 -macroglobulin activity. α_2 -antiplasmin-depleted plasma was obtained by passing normal plasma through a Krings 1-3-Sepharose column as described by *Wiman* (1980). α_2 -Macroglobulin-inactivated plasma was obtained by treatment of normal plasma with 0.1M methylamine *Barrett et al.* (1979) for 2 hours at 37°C with subsequent dialysis against PBS at 4°C.

Using the above-described thrombolysis assay, it was shown that plasmin was capable of dissolving plasma thrombi in a dose-dependent manner as shown in Figs. 5 and 6. Increasing amounts of plasmin were added to ^{125}I fibrin-labeled plasma thrombi and the degree of thrombolysis was assessed by measuring the release of radioactivity: (a) 0.15 mg/ml of plasmin in the reaction tube, (b) 0.30 mg/ml; (c) 0.45 mg/ml; (d) 0.60 mg/ml; (e) control with no plasmin added. The data in Fig. 6 demonstrate that plasmin is also active in a plasma environment and is capable of dissolving plasma thrombi. This phenomenon is dose-dependent. At the same time, unlike with the Lys-plasminogen and tPA mixture, thrombolysis by plasmin alone does not progress to completion in a plasma environment; thrombolysis tends to cease

after 2 hours. While not wishing to be bound by any one theory, this phenomenon can be explained by the presence of various protease inhibitors in a plasma environment and, especially by rapid inhibition of non-thrombus-bound plasmin by α_2 -antiplasmin.

To assess the role of plasma inhibitors in plasmin-catalyzed thrombus lysis, a 5 series of thrombolysis experiments was performed with normal plasma and plasma samples lacking α_2 -antiplasmin, α_2 -macroglobulin or all the inhibitors, or PBS.

As seen from Fig. 6, plasmin-induced fibrinolysis was enhanced by deletion of either α_2 -antiplasmin or α_2 -macroglobulin in the plasma surrounding the thrombus, and even more so by the deletion of all inhibitors. These results confirm that 10 thrombolysis by plasmin is under very strict physiologic control by the endogenous plasma plasmin inhibitors, thus providing a basis for safer thrombolytic therapy.

In contrast to plasminogen activator-induced thrombolysis, thrombolysis with plasmin can be controlled by these inhibitors. Plasminogen activator-induced thrombolysis utilizes the internal source of plasminogen present in plasma that, from 15 the practical point of view, is unlimited in a human body. On the other hand, plasmin-induced thrombolysis entirely depends on the external source of the plasmin. Cessation of plasmin administration to the patient should result in rapid cessation of thrombolysis and provides a basis for safer thrombolytic therapy.

20 **Example 6: Comparison of reversibly inactivated acidified plasmin and tPA in an *in vitro* model of Peripheral Arterial Occlusion (PAO)**

Aged, retracted clots are deficient in plasminogen, the substrate required by all plasminogen activators for effective clot lysis. *Robbie et al.* Thrombosis and

Haemostasis, 1996, 75(1), 127-33. Aged clots are significantly less susceptible to lysis by plasminogen activators.

Aged clots differ from clots causing myocardial infarction or stroke both mechanically and in their protein composition. They are typically found in the 5 peripheral arteries and can grow to a significant size. The average size of a peripheral clot found in the native arteries is 14.8 ± 11 cm as described in *Ouriel et al.* Current thrombolytics represented exclusively by plasminogen activators are almost ineffective in lysis of these types of clots. Typically, a patient with PAO is treated for more than 24 hours with urokinase and even after this prolonged time, the complete 10 patency of the vessel is not achieved. The situation may be exacerbated when the thrombolytics are delivered via catheter into the interior of the clot, further preventing the access of the plasminogen substrate required for their efficacy.

Another approach to the lysis of retracted clots is the direct delivery of active 15 plasmin via a catheter, into the interior of the clot. Delivery of reversibly inactivated acidified plasmin directly into retracted clots circumvents the inherent plasminogen deficiency of these clots and provides predictable, rapid and effective clot thrombolysis irrespective of plasminogen content. Moreover, the abundant presence 20 of the natural plasmin inhibitor, α_2 -antiplasmin, in plasma serves to instantaneously inactivate any plasmin which escapes from the vicinity of the clot, thereby preventing distal fibrinolysis and consequent bleeding episodes.

To compare the efficacy of plasmin and tPA toward the lysis of long retracted clots, we have developed an *in vitro* model that mimics parameters of the clots formed in patients with PAO.

In Vitro PAO Model. Fresh whole human blood was collected into 30 x 0.95

cm glass tubes and allowed to clot spontaneously without additives. Tubes were incubated for 20 hours at 37°C to allow full retraction. Retracted clots were separated from serum using USA Standard testing sieves D16 with 14 mesh and their weights were determined. Blood clots were transferred into smaller diameter glass tubes that 5 resembled the average size clots in leg arteries (0.6 x 12 cm). A multi-side port pulse-spray catheter (French size 5 with the 11 cm spraying tip, Cook, Inc.) was inserted into the clot and a thrombolytic reversibly inactivated acidified plasmin composition according to the present invention, or tPA) at 1 mg/ml was delivered in 1-ml increments separated by 1 hour time intervals. The number of injections corresponds 10 to the dose of thrombolytic. The extent of clot lysis was measured by the weight of a residual clot and expressed as a percent of clot weight reduction. This model is called a PAO model. It mimics the dimensions of the thrombi found in PAO patients, although venous blood was used for clot formation. Both tPA and the reversibly inactivated acidified plasmin composition according to the present invention were 15 tested in this model and the results are presented below.

Plasmin is as effective as tPA for lysis of fresh clots, unlike when tPA and plasmin are used for lysis of retracted clots aged for 20 hours to allow complete cross-linking by Factor XIII. tPA is unable to lyse such clots. Clot weight reduction obtained with tPA-treated clots is similar to the control, even when the dose is raised 20 up to 5 mg per clot.

Plasmin, on the other hand, is effective toward fully retracted and cross-linked clots. There is a dose-dependence of the lytic effect of plasmin and after five injections (or 5 mg plasmin in total) the clots are almost completely lysed. In a similar series of experiments, the same inability to dissolve retracted and cross-linked

human thrombi was observed with urokinase. Locally delivered plasmin therefore is a more effective thrombolytic agent than tPA and other plasminogen activators.

These *in vitro* data show that tPA requires the presence of its substrate, plasminogen, in the clot to initiate and maintain clot lysis. Therefore, while plasmin 5 is as effective as tPA for lysing fresh or plasminogen-rich clots, plasmin is more effective than tPA, and other plasminogen activators, for lysing of long retracted plasminogen-poor clots. Moreover, the data presented in this example demonstrates that plasmin is effective in its reversibly inactivated acidified form when it is injected directly inside the clot.

10 The clots in the glass tubes are also a model wherein a thrombus or fibrin plug forms in catheters placed in a human or animal and the catheter is occluded.

Example 7: Rabbit jugular vein thrombosis model.

The *in vivo* efficacy and safety of locally administered active plasmin was 15 determined by the rabbit jugular vein thrombosis model of *Collen et al.*, (1983). The model, in brief was as follows: Rabbits (2-3 kg) are sedated with ketamine/xylazine and a 22G venous catheter was placed in the ear vein for administration of a dilute solution of pentobarbital (5-10 mg/kg/hr). The neck was shaved and an arterial catheter was placed in the carotid artery for pressure measurements and blood 20 sampling. A tracheotomy was performed for placement of a tracheal tube to facilitate breathing. The jugular vein was carefully isolated with blunt dissection up to and including the facial vein. A 24G catheter was placed in the facial vein and the jugular vein clamped both distal and proximal to the isolated facial vein. The isolated vein segment was washed several times with saline and completely drained of blood. The

isolated segment was washed several times with a thrombin solution (500 U/ml). Following the last wash, 0.5 ml of arterial blood sample was drawn from the arterial catheter and mixed quickly with 50 μ l of 125 I-labelled fibrinogen (approximately 1 μ Ci). The mixture was rapidly infused into the isolated vein segment via the facial vein until the vein segment was fully distended. The thrombus was mixed by massaging the vein with forceps and a piece of Saran Wrap placed over the exposed jugular vein to prevent drying. Heparin (100 IU/kg) was administered to prevent the deposition of cold fibrinogen on thrombus. The thrombus was allowed to age for 30 minutes and clips were removed.

10 The stability of the thrombus is monitored over a 30-minute equilibration period. Dissolution of the labeled thrombus (% lysis) was monitored continuously with a G1LE gamma counter probe placed directly over the thrombus.

Example 8: Restoration of venous flow.

15 To provide a physiologic readout of thrombus dissolution, blood flow restoration was used as another index of thrombolysis in a separate series of experiments. In these experiments, an appropriately sized flow probe was placed distal to the occlusive thrombus (not radiolabeled) connected to a Transonic Flowmeter and venous blood flow measurements were taken every minute.

20 Baseline blood flow before thrombus formation was 12-18 ml/min and data is represented as % of baseline. The percent restoration of venous blood flow and the consumption of Factor VIII and fibrinogen are shown at 60 minutes in Fig. 7, and at 90 minutes in Fig. 8. At doses of 0.5 mg/kg and 1.0 mg/kg, tPA induced $16 \pm 4\%$ and $21 \pm 10\%$ restoration of baseline blood flow at 60 minutes, respectively. Plasmin at

1.0 mg/kg and 2.0 mg/kg induced $20 \pm 1\%$ and $33 \pm 1\%$ restoration of baseline blood flow, respectively. At 90 minutes, tPA infusion resulted in $18 \pm 3\%$ and $26 \pm 11\%$ restoration of blood flow, respectively and plasmin had resulted in $25 \pm 5\%$ and $34 \pm 6\%$ restoration of flow, respectively.

5

Example 9: Cuticle bleeding times (CBT).

Cuticle bleeding times at 60 minutes are shown in Fig. 9. Saline treatment resulted in bleeding times of 13 ± 1 minutes. tPA at doses of 0.5 mg/kg and 1.0 mg/kg resulted in bleeding times of 13 ± 2 minutes and 25 ± 4 minutes, respectively, 10 whereas plasmin, at doses of 1.0 mg/kg and 2.0 mg/kg resulted in bleeding times of 17 ± 3 and 19 ± 1 minutes, respectively. tPA shows a prolonged CBT compared to when reversibly inactivated acidified plasmin is used, demonstrating that systemic fibrinolysis by tPA activation of endogenous plasminogen is more extensive than if plasmin is administered and rapidly inhibited by serum factors.

15

Example 10: Rabbit fibrinolytic hemorrhage model

The greater safety of plasmin, relative to the plasminogen activator tPA, was demonstrated in an established rabbit model of fibrinolytic bleeding that represents a valid indication of fibrinolytic hemorrhage, as described in *Marder et al.*, (1992).

20 Thrombolytically equivalent doses (10 ml volumes) of plasmin and tPA were compared in ear-puncture model for their relative effects on the occurrence and duration of re-bleeding, and on selected plasma coagulation and fibrinolytic parameters. Two different doses of plasmin (2.0 or 4.0 mg/kg) or tPA (1.0 or 2.0 mg/kg) were infused over 60-minute periods into rabbits through a catheter inserted

into the external jugular vein. Ear punctures (approximately six per ear) with a scalpel blade prior to, during, and after infusion of each fibrinolytic agent were observed for both bleeding time and for re-bleeding. Primary bleeding times were performed at minus 30, minus 10, 0, 10, 30, 60, 70, 90, 120 and 180 minutes relative to the start of each infusion. Citrated blood samples (5 ml) were obtained before, during, and for up to two hours after infusion of each fibrinolytic agent; these blood samples were assayed for fibrinogen, Factor VIII, and α_2 -antiplasmin. Each experimental group consisted of five rabbits.

The primary bleeding times tended to be longer for the tPA groups at each time point after initiation of infusion until the 90-minute point (Table 4).

Table 4. Primary bleeding times.

Experimental Group	Mean Bleeding Time for Group (Minutes) at Different Times (Minutes) Relative to the Start of Infusion									
	-30	-10	0	10	30	60	70	90	120	180
tPA (1.0 mg/kg)	2.2	1.7	1.4	3.3	2.8	2.5	1.6	1.6	1.2	2.4
tPA (2.0 mg/kg)	1.7	1.9	1.6	1.6	2.7*	3.9	3.0*	2.3	1.7	1.0
Plasmin (2.0 mg/kg)	1.6	1.7	1.8	2.0	1.9	2.5	1.8	2.2	2.0	1.7
Plasmin (4.0 mg/kg)	1.5	1.5	1.4	2.3	1.1*	2.8	1.4*	0.9	1.4	1.5

*Statistically greater than the corresponding mean values observed with the indicated plasmin groups (p<0.05).

This effect was statistically significant (p<0.05) in the comparison of the high-dose groups of tPA and plasmin at the 30-minute and 70-minute experimental times.

Table 5 shows the observed occurrence of re-bleeding in each of the four

experimental groups.

Table 5. Occurrence of Re-bleeding in Each Experimental Group

Experimental Group	Number of Animals Exhibiting Re-Bleeding
tPA (1.0 mg/kg)	5 out of 5
tPA (2.0 mg/kg)	4 out of 5
Plasmin (2.0 mg/kg)	0 out of 5
Plasmin (4.0 mg/kg)	0 out of 5
tPA combined groups (n=10)	9 out of 10
Plasmin combined	0 out of 10

5 The results distinguish the hemorrhagic activity of the plasminogen activator, tPA, from that of plasmin. None of the plasmin-treated animals exhibited re-bleeding, unlike nine out of ten of the tPA-treated animals.

Table 6A summarizes the mean re-bleeding times at active sites and at all sites of re-bleeding for the 1.0 mg/kg tPA dosage group. Table 6B summarizes the 10 corresponding data for the 2.0 mg/kg dosage group.

Table 6A. Mean Re-bleeding Times in Rabbits Receiving tPA at 1.0 mg/kg

	Time Relative to Start of Infusion (Minutes)									
	-30	-10	0	10	30	60	70	90	120	180
Percentage of sites that re-bled	60	60	80	100	80	20	20	0	0	0
Mean re-bleeding time (minutes) of active sites	2.0	4.0	31.3	20.7	9.0	1.5	1.0	--	--	--
Mean re-bleeding time (minutes) of all sites	1.2	2.4	25.0	20.7	7.2	0.3	0.2	--	--	--

Table 6B. Mean Re-bleeding Times in Rabbits Receiving tPA at 2.0 mg/kg

	<u>Time Relative to Start of Infusion (Minutes)</u>									
	-30	-10	0	10	30	60	70	90	120	180
Percentage of sites that re-bled	40	80	60	80	60	40	0	0	0	0
Mean re-bleeding time (minutes) of active sites	32	23	44.7	68.4	48.7	2.5	--	--	--	--
Mean re-bleeding time (minutes) of all sites	12.8	18.4	26.8	54.7	7.2	29.2	--	--	--	--

Re-bleeding at active sites showed a distinction between the two dosage groups for tPA, with longer duration of re-bleeding at the 2.0 mg/kg dose relative to 5 the 1.0 mg/kg dose of tPA. The results from blood chemistry measurements are summarized in Tables 7-9.

Table 7 presents the levels of fibrinogen measured at the experimental times. The mean fibrinogen levels following tPA infusion fell more rapidly and to a lower nadir than following the plasmin infusions.

10 Table 7. Mean Fibrinogen Levels (mg/dl) in Experimental Groups at Different Times (Minutes) Relative to Start of 60-Minute Infusion

Experimental Group	<u>Time Relative to Start of Infusion (Minutes)</u>							
	-30	0	10	60	70	90	120	180
tPA (1.0 mg/kg)	221	205	202	93	145	126	194	205
tPA (2.0 mg/kg)	260	233	151	118	196	190	214	160
Plasmin (2.0 mg/kg)	208	231	214	149	167	134	183	145
Plasmin (4.0 mg/kg)	297	293	256	222	146	184	159	140

--	--	--	--	--	--	--	--

The mean values for Factor VIII (Table 8) were lower at most of the experimental times for the tPA-infused animals relative to the plasmin-infused animals, with statistical significance being reached at the 60-minute experimental time for each tPA group versus each plasmin group.

Table 8. Mean Factor VIII Levels (Percent of Initial) in Experimental Groups at Different Times (Minutes) Relative to Start of 60-Minute Infusion

Experimental Groups	Time Relative to Start of Infusion (Minutes)							
	-30	0	10	60	70	90	120	180
tPA (1.0 mg/kg)	(100)	87	84	23*	58	77	57	64
tPA (2.0 mg/kg)	(100)	85	56	29*	41	36	46	44
Plasmin (2.0 mg/kg)	(100)	108	87	77	62	56	72	78
Plasmin (4.0 mg/kg)	(100)	85	65	58	58	61	47	50

*Statistically lower than the corresponding mean values for either of the plasmin groups at 60 minutes (p<0.05).

Recovery of Factor VIII in animals receiving tPA was to approximately the same concentration (50-60% of initial values) as with animals receiving plasmin. Comparison of the two doses of tPA shows a more rapid decrease in Factor VIII with the higher dose and a more dramatic rebound increase in Factor VIII with the lower dose.

The mean values for α_2 -antiplasmin as shown in Table 9 were lower at most of the experimental times for the tPA-infused animals relative to the plasmin-infused animals.

Table 9. Mean α_2 -Antiplasmin Levels (Percent of Initial) in Experimental Groups at Different Times (Minutes) Relative to Start of 60-Minute Infusion

Experimental Group	Time Relative to Start of Infusion (Minutes)							
	-30	0	10	60	70	90	120	180
tPA (1.0 mg/kg)	(100)	100	39*	4*	34	37	51	43
tPA (2.0 mg/kg)	(100)	81	12*	0*	9**	15**	15	27
Plasmin (2.0 mg/kg)	(100)	104	93	55	55	56	45	79
Plasmin (4.0 mg/kg)	(100)	102	89	45	20	49	24	24

*Statistically lower than the corresponding mean values for either of the plasmin

5 groups at these experimental times (p<0.05).

**Statistically lower than the mean values for the low-dose plasmin groups at these experimental times (p<0.05).

Statistical significance was reached at the 10-minute and 60-minute experimental

10 times between each of the tPA groups and either of the plasmin groups and at the 70-minute and 90-minute experimental times between the high-dose tPA groups and the corresponding low-dose plasmin groups.

Example 11: Fibrinolysis by mini-plasmin

15 Mini-plasmin is a truncated version of plasmin lacking the first four kringle domains. It can be produced from mini-plasminogen that is generated by limited proteolysis of plasminogen with elastase. Mini-plasmin will be more effective for clot lysis than full-sized plasmin since: (a) mini-plasmin is smaller than plasmin (38 kDa vs 84 kDa) and will more easily diffuse inside the clot; and (b) mini-plasmin

20 lacks the α_2 -antiplasmin binding site of kringle 1, and therefore will be resistant to

inhibition by α_2 -antiplasmin cross-linked to the clot. α_2 -Antiplasmin is often responsible for resistance of aged clots to thrombolytic therapy. Mini-plasminogen was purified as described in *Sottrup-Jensen et al.* (1975). Mini-plasminogen conversion into mini-plasmin, its purification and formulation were accomplished 5 using exactly the protocol as described for plasmin of the Example 2.

The thrombolytic potency of mini-plasmin was compared with that of plasmin at equimolar concentrations using the *in vitro* PAO model described in Example 6. Clots were aged for 20 hours and two 1-ml doses of plasmin (1 mg/ml) or mini-plasmin (0.45 mg/ml) were delivered to the clot via a catheter. Between injections, 10 clots were incubated at 37°C for 1 hour. The extent of thrombolysis was measured by clot weight reduction. Clots infused with saline were used as control. Clot dimensions – 0.6 x 12 cm.

As shown in Fig. 10, mini-plasmin causes greater clot lysis than plasmin when used in the equimolar amounts. The clot weight reduction after two 1-ml injections of 15 mini-plasmin at 0.45 mg/ml was $44.3 \pm 4.4\%$. whereas two 1-ml injections of plasmin at 1 mg/ml resulted in $36 \pm 1.7\%$ clot weight reduction. Mini-plasmin can be an even more effective thrombolytic agent than plasmin when delivered through the catheter directly to or inside the clot.

20 **Example 12: Efficacy of localized catheter plasmin administration of plasmin**

The *in vivo* efficacy of plasmin (1-2 mg/kg) administered locally via a catheter was compared with that of tPA (0.5 and 1.0 mg/kg) in the rabbit jugular vein thrombosis model. Two approaches were used to assess thrombolysis: 1) real-time measurements of percent lysis with a radiolabeled thrombus; and 2) restoration of

baseline blood flow via the application of a flow probe and flow meter. The rate of thrombolysis was monitored and quantified over 90 minutes, as described in Example 6. Concomitantly, the consumption of Factor VIII and fibrinogen, as well as cuticle bleeding time (CBT), were measured as indicators of the systemic lytic state. For 5 these local administration studies, a catheter (PE 50) was advanced via the marginal ear vein, to within 1 cm of the obstructive thrombus. Two doses of tPA; 0.5 and 1.0 mg/kg and two doses of plasmin; 1.0 mg/kg and 2 mg/kg were used. These doses were contained in 10.0 ml total volume infused over 30 minutes. The percent lysis at 60 and 90 minutes with the radiolabeled thrombus was measured and, in another 10 separate series of experiments with unlabelled thrombi, percent restoration of flow was measured at similar time points. Arterial blood samples (4 ml) obtained at 0 minutes and 60 minutes were used for determination of fibrinogen and Factor VIII levels. Factor VIII levels and fibrinogen concentrations were determined using a MLA Electra 800 Coagulation Timer and the Fibrinogen Assay Set. Factor VIII 15 levels were determined by the COATEST VIII C4 assay using human Factor VII to generate a standard curve. Cuticle bleeding times at 0 minutes and 60 minutes were determined by clipping the rabbit's nail, at the apex, with a dog nail trimmer. The blood was dabbed, without touching the nail, with a filter paper every two minutes until a thrombus formed and the filter paper did not wick blood away. Results are 20 represented as Mean \pm SEM, and to evaluate significant differences between groups a one-way ANOVA followed by Bonferroni's procedure for multiple-comparison testing was used. P<0.05 was considered significant.

Plasmin or tPA (total volume 10 ml) was infused over 30 minutes via a catheter placed 1 cm proximal to the thrombus. An equal volume of saline served as a

control. Plasmin doses of 1.0-2.0 mg/kg were compared to a 0.5 mg/kg dose of tPA. A one-way ANOVA followed by Dunn's method for multiple comparison testing was used for statistical evaluation, (* p<0.05 compared to tPA at 0.5 mg/kg, or # vs tPA at 1.0 mg/kg).

5 When compared with tPA (0.5 -1.0 mg/kg), plasmin (1.0-2.0 mg/kg) infused locally induced comparable or significantly better thrombolysis, with similar or less consumption of Factor VIII and fibrinogen and CBT. Risk/benefit evaluation of plasmin treatment revealed that twice the dose of plasmin (on a weight basis) induced similar bleeding side effects as did tPA. Thus, plasmin can be effectively and safely
10 used as a thrombolytic agent during catheter-assisted local thrombolysis. Plasmin has comparable or superior lytic activity when compared to tPA, and the safety profile appeared similar in this animal model of local thrombolytic delivery.

15 The extent of thrombolysis was calculated from the ratio between the amount of radioactivity released from the thrombus into the plasma and the total amount of radioactivity in the reaction tube. The release of labeled fibrin degradation products, expressed in percent, was plotted versus time.

20 The percent lysis of radiolabeled thrombi and consumption of Factor VIII and fibrinogen are shown at 60 minutes (Fig. 11) and 90 minutes incubation periods (Fig. 12). At 0.5 mg/kg and 1.0 mg/kg, tPA induced 16 \pm 2% and 21 \pm 2% lysis, respectively, whereas plasmin at 1.0 mg/kg and 2.0 mg/kg induced 26 \pm 3% and 33 \pm 4% lysis, respectively. At 90 minutes, tPA infusion had resulted in 21 \pm 2% and 26 \pm 2% lysis, respectively, compared to plasmin which induced lysis of 31 \pm 4% and 36 \pm 2%, respectively.

Example 13: Risk/benefit assessment of plasmin treatment vs tPA treatment.

An extensive comparative pharmacological evaluation (risk/benefit) of plasmin in the rabbit model of thrombolysis was determined. The efficacy of plasmin was compared with that of tPA. Percent lysis and restoration of blood flow as indices of efficacy were used. These analysis were performed in separate experiments. The respective side effects induced by these thrombolytic agents were compared by measuring the consumption of Factor VIII and fibrinogen and assessing bleeding times. This allowed a determination of an approximate risk/benefit profile.

To determine the risk profile, the ED₅₀ dose for tPA was calculated, using the consumption of Factor VIII as a surrogate marker for induction of the lytic state and bleeding. The consumption of Factor VIII was directly related to the bleeding side effect by replenishing back Factor VIII (Kogenatee) and returning normal hemostasis. tPA doses ranging from 0.1 mg/kg to 3.0 mg/kg with a N of at least 10 animals/dose were examined. 1.0 mg/kg is considered a clinical dose for tPA. The calculated ED₅₀ for tPA was 1.8 mg/kg. A similar calculation for locally administered plasmin gave an ED₅₀ of 3.6 mg/kg. Therefore, twice the dose of plasmin (wt basis) induced similar bleeding side effects as tPA. The efficacy (% lysis and blood flow) with doses of tPA and plasmin with equivalent risk profiles i.e., consumption of coagulation proteins and bleeding were evaluated as shown in Fig. 13. At all equivalent risk doses tested, tPA (0.5 - 3.0 mg/kg) and plasmin (1.0 - 3.0 mg/kg), plasmin induced at least similar or significantly better rates of lysis and restoration of blood flow compared to tPA. The pharmacological data, therefore, is sufficient to recommend that plasmin be considered for the lytic treatment of thrombi accessible by catheter placement.

Example 14: Degradation peptides of plasmin samples characterized by N-terminal sequencing.

The degradation peptides of plasmin samples were characterized by N-terminal sequencing as follows. Plasmin compositions were formulated at low pH values: a pH less than 2.5 and a pH of 3.5 and 3.8 containing 2 mM acetic acid. The plasmin samples were analyzed using SDS-PAGE with 4 – 12% Bis-Tris NuPage gels, as shown in Fig. 14. The protein bands were transferred to a PVDF membrane, stained with Coomassie Blue R-250 (Bio-RAD Laboratories, Hercules, CA) and bands cut out using a scalpel.

10 N-terminal sequence analysis was performed directly from the membrane using a Hewlett Packard 241 Protein Sequencer (Hewlett Packard, Inc., Glen Allen, VA). Ten cycles were run for each band so that the corresponding fragment of plasmin could be identified. Molecular weights for each band were determined with densitometry analysis using the Mark 12 marker available from Invitrogen, Inc. (San 15 Diego, CA)

Three polypeptides generated by incubation of plasmin at pH 3.8 began at positions (numbering relative to Lys-plasmin) threonine (T105), glycine (G190) and glutamic acid (E623). From the known amino acid sequence of plasmin, it was determined that the first two polypeptides were from the heavy chain and the third 20 from the light chain. As shown in Fig. 15, the amino acid preceding the N-terminal amino acid was either arginine or lysine (K104, R189, and K622). It is commonly known that plasmin cleaves proteins on the carboxyl side of lysine and arginine. These results demonstrated that compositions of plasmin at pH 3.8 were susceptible to autodegradation.

Three polypeptides generated by incubation of plasmin at pH 2.2 began with proline at the N-termini. From the known amino acid sequence of plasmin, it was determined that these polypeptides were from the heavy chain, starting at positions P63, P155, and P347, as shown in Fig. 15. The amino acid preceding each proline 5 was an aspartic acid (D62, D154, and D346). It is commonly known that aspartyl-prolyl (D-P) peptide bonds are acid labile. These results demonstrated that compositions of plasmin at pH 2.2 were susceptible to acid hydrolysis of peptide bonds.

10

Example 15: Sugars in low pH formulation stabilize plasmin.

Plasmin was formulated in one of the following acids with at least one of the following sugars, at pH 2.5 to 4.0. The group of acids included 1 mM to 500 mM of acetic acid, citric acid, serine, threonine, isoleucine, valine, glutamine, β -alanine, or other acids, preferable in the range of 1 mM to 50 mM. The group of sugars included 15 0.2% to 20% of maltose, mannitol, sorbitol, sucrose, lactose, glucose and trehalose. The plasmin formulation without any excipient was included as a control. All samples were incubated at 37°C for 7 days. The change in plasmin integrity was analyzed by running reducing SDS-PAGE.

The results shown in Fig. 16 demonstrate that sugars have a stabilizing effect 20 on plasmin at pH 3.5 and improve the benefits from storing reversibly inactivated acidified plasmin at low pH.

Example 16: Stabilization of reversibly inactivated acidified plasmin

composition with non-carbohydrate stabilizing agents

Reversibly inactivated acidified compositions were formulated at 1mg/ml in 5 mM acetic acid, pH 3.7, according to the present invention, with 0.1M of glucosamine, niacinamide, citrulline or thiamine added as a non-carbohydrate 5 stabilizer. A reversibly inactivated acidified plasmin formulation without any excipient stabilizing agent was included as a control. All samples were incubated at 37° C for 7 days and the change in plasmin integrity analyzed using SDS-PAGE under non-reducing conditions. Referring now to Fig. 17, all of the non-sugar stabilizing agents tested improved the stability of the reversibly inactivated acidified 10 plasmin composition at 37° C over the 7day test period.

A reversibly inactivated acidified plasmin compositions was also formulated at 1mg/ml in 2 mM acetic acid, pH 3.4, according to the present invention, with 150 mM sodium chloride as a stabilizing agent. The same formulation, but without sodium chloride, was also prepared and included as a control. Samples were 15 incubated at 4°C for 28 days. The change in plasmin integrity was analyzed using SDS-PAGE under non-reducing conditions, as described in Example 3 above. Values were normalized relative to day 0 controls which were assigned a value of 100%. Table 5, the results demonstrate that plasmin stored at 4oC is more stable in the low-pH formulation containing sodium chloride.

20 Table 5. Stability of reversibly inactivated acidified plasmin composition (2mM NaAc, pH 3.4) with or without 150 mM sodium chloride, stored at 4°C.

Sodium chloride Concentration (mM)	Plasmin (mg/ml)	% intact heavy chain after 28 days	% intact light chain after 28 days	% activity after 28 days
0	1	90	93	81

150	1	101	95	97
-----	---	-----	----	----

Example 17: Plasma can neutralize proportionally large volumes of acidified saline.

In order to estimate the volume of reversibly inactivated acidified plasmin compositions of the present invention that can be neutralized by one milliliter of serum at physiological pH, a series of titration experiments were performed. A 1-ml volume of serum is estimated to represent the liquid phase volume of an average retracted clot found in the artery of a PAO patient. Serum (1 ml) was titrated with an acidified (pH 3.7) low buffering capacity buffer solution typical of that in which reversibly inactivated acidified plasmin according to the present invention is formulated. As shown in Fig. 18, 1 ml of serum is capable of neutralizing approximately 150 ml of acidified saline. The latter volume will exceed the likely volume of reversibly inactivated acidified plasmin required for treatment of peripheral arterial occlusions.

Thus, the formulation of reversibly inactivated acidified plasmin in a low buffering capacity buffer provides the basis for an effective and stable pharmaceutical composition. Such compositions would allow administration of reversibly inactivated acidified plasmin at room temperature for the time required for treatment without the plasmin significantly losing potency during delivery of the preparation to the patient.

20

Example 18: Trypsin stabilized at low pH can be reactivated by transfer to higher pH environment

Trypsin (16.4 mg, Sigma Chemical Co. Catalog No. T-1426) was dissolved in

2.28 ml of 50 mM Tris/0.5 M NaCl (pH 8.0). The trypsin solution was loaded onto a 1-ml column of Benzamidine-Sepharose (Pharmacia Code No. 17-0568-01) that had been pre-equilibrated with 50 mM Tris/0.5 M NaCl (pH 8.0). This column was washed with 4 ml of this latter buffer, resulting in a decrease in the eluate absorbance 5 (280 nm) to less than 0.03. Trypsin was eluted from this column in an inactivated state with 0.5-ml volumes of 200 mM glycine/0.5 M NaCl (pH 3.0); the third through fifth 0.5-ml fractions eluted from this column contained the peak values of absorbance (280 nm) and were pooled. The absorbance (280 nm) of this pooled trypsin eluate was determined to be 9.22; based upon the extinction coefficient for trypsin (E_{280} for a 10 1% solution = 17.09) and the molecular weight of trypsin (24,000), the concentration of total trypsin protein in this pooled column eluate was calculated to be 225 μ M.

The concentration of trypsin active sites in this pooled trypsin column eluate was determined by the method described by *Case & Shaw*, *Biochem. Biophys. Res. Commun.* 29, 508 (1967) and incorporated herein by reference in its entirety, using *p*-nitrophenylguanidinobenzoate as active-site titrant. This assay was performed at pH 15 8.3, by diluting a small volume (100 μ l) of the pooled trypsin column eluate into an assay mixture also containing 700 μ l of 50 mM sodium borate (pH 8.3), 200 μ l of 10 mM sodium phosphate/1% glycine (pH 7.0) plus 10 μ l of *p*-nitrophenylguanidinobenzoate (dissolved in dimethyl formamide); the final pH of 20 this mixture composition was determined to be 8.3. The trypsin-dependent amount of *p*-nitrophenol formed in this assay was monitored at 410 nm. Based upon the extinction coefficient for *p*-nitrophenol at 410 nm and at pH 8.3 ($16,595 \text{ M}^{-1}$), 100 μ l of this pooled trypsin column eluate present in the 1.01-ml assay corresponded to a concentration of 22.95 μ M trypsin active sites present in the cuvette. Therefore, the

original stock solution of pooled trypsin column eluate contained 231 μ M trypsin active sites. This latter value is identical, within experimental error, to the concentration of total trypsin protein present (225 μ M). These results demonstrate that trypsin can be adjusted to low pH and then transferred to a higher pH 5 environment with reactivation of its active site.

References

The following references are specifically incorporated herein by reference:

- 10 *Deutsch, D.G. & Mertz, E.T.*, Science 170, 1095-1096. (1970)
Robbins, K.C. & Summaria, L. Meth. Enzymol., 19, 257-273 (1970)
Castellino, F.J. & Powell, JR. Meth. Enzymol., 80, 365-378. (1981)
Lijnen, H.R., Zamarron, C., Blaber, M., Winkler, M.E. & Collen, D. J. Biol.Chem. 261, 1253-1258 (1986)
- 15 *Wiman, B.*, Biochem. Journal. 191(l):229-32(1980)
Barrett, A.J., Brown, M.A., & Sayers, C.A., 181, 401-418 (1979)
Collen, D., Stassen, J.M.. & Verstraete, M., J. Clin. Invest. 71(2), 368-376 (1983)
Marder, V.J., Shortell, C.K., Fitzpatrick, P.G., Kim, C. & Oxley, D. Thrombosis Res. 67, 31-40 (1992)

20

U.S Patent Nos:

5,288,489

3,950,513

5,879,923

What is Claimed Is:

1. A method of administering a therapeutic dose of a reversibly inactivated acidified fibrinolytic composition to a human or animal having a thrombotic occlusion, comprising the steps of:
 - 5 a) identifying a human or animal having a thrombotic occlusion; and
 - b) administering parenterally to the human or animal a therapeutic dose of a pharmaceutically acceptable reversibly inactivated acidified fibrinolytic composition substantially free of plasminogen activator, wherein the therapeutic dose is delivered into or proximally to the thrombotic occlusion.
- 10 2. The method of Claim 1, further comprising the step:
 - 15 c) allowing the administered fibrinolytic composition to interact with the thrombotic occlusion;
3. The method of Claim 2, further comprising the steps:
 - 20 d) monitoring the level of vascular flow of the human or animal; and
 - e) repeating steps (a) – (d) until a pre-selected level of vascular flow is attained.
4. The method of Claim 1, wherein the thrombotic occlusion is a vascular

occlusion selected from a coronary thrombosis, deep venous thrombosis, peripheral thrombosis, embolic thrombosis, hepatic vein thrombosis, marasmic thrombosis, sinus thrombosis, venous thrombosis, an arterial thrombosis, an occluded arterio-venal shunt, or an occluded catheter device.

5

5. The method of Claim 1, wherein the reversibly inactivated acidified fibrinolytic composition comprises a reversible inactivated acidified fibrinolytic enzyme and a pharmaceutically acceptable acidified carrier, wherein the pharmaceutically acceptable carrier is a low buffering capacity buffer.

10

6. The method of Claim 1, wherein the reversibly inactivated acidified fibrinolytic composition is lyophilized, and wherein the method of Claim 1 further comprises the step of adding a pharmaceutically acceptable carrier to the lyophilized fibrinolytic composition before administration to the human or animal.

15

7. The method of Claim 5, wherein the reversibly inactivated acidified fibrinolytic enzyme is a mammalian serine protease.

20

8. The method of Claim 5, wherein the reversibly inactivated acidified fibrinolytic enzyme is Glu-plasmin, Lys-plasmin, mini-plasmin, micro-plasmin, or a truncated variant thereof.

9. The method of Claim 5, wherein the reversibly inactivated acidified fibrinolytic composition is further comprising an anti-thrombotic agent.

10. The method of Claim 5, wherein the pharmaceutically acceptable acidified carrier is a low buffering capacity buffer comprising water and at least one pharmaceutically acceptable acid, wherein the acid is an organic acid selected from a 5 carboxylic acid, an oligopeptide, an amino acid, or an inorganic acid, and the acidified carrier has a pH less than about 4.0.

11. The method of Claim 10, wherein the pharmaceutically acceptable acid is selected from formic acid, acetic acid, citric acid, glycine, isoleucine, serine, 10 threonine, glutamine, aspartic acid, valine and alanine, and the acidified carrier has a pH less than about 4.0.

12. The method of Claim 10, wherein the pharmaceutically acceptable acid is acetic acid or citric acid.

15

13. The method of Claim 10, wherein the pharmaceutically acceptable acid is acetic acid.

14. The method of Claim 1, wherein the reversibly inactivated acidified 20 fibrinolytic composition has a pH of between about 2.5 and about 4.0.

15. The method of Claim 1, wherein the reversibly inactivated acidified fibrinolytic composition has a pH of between about 3.0 and about 4.0.

16. The method of Claim 1, wherein the reversibly inactivated acidified fibrinolytic composition has a pH of between about 3.1 and about 3.5.

17. The method of Claim 7, wherein the mammalian serine protease is in the 5 concentration range of between about 0.01 mg/ml to about 50 mg/ml.

18. The method of Claim 7, wherein the mammalian serine protease is in the concentration range of between about 0.1 mg/ml to about 10 mg/ml.

10 19. The method of Claim 10, wherein the acid is in the concentration range of between about 1 mM to about 500 mM.

20. The method of Claim 10, wherein the acid is in the concentration range of between about 1 mM and 50 mM.

15

21. The method of Claim 5, wherein the reversibly inactivated acidified fibrinolytic composition further comprises a stabilizing agent.

22. The method of Claim 21, wherein the stabilizing agent is a pharmaceutically 20 acceptable carbohydrate selected from glucose, maltose, mannitol, sorbitol, sucrose, lactose or trehalose.

23. The method of Claim 22, wherein the carbohydrate has a concentration in the range of about 0.2% w/v to about 20% w/v.

24. The method of Claim 22, wherein the carbohydrate is glucose and the concentration thereof is about 20%.

5 25. The method of Claim 22, wherein the stabilizing agent is selected from glucosamine, niacinamide and thiamine.

26. The method of Claim 22, wherein the stabilizing agent has a concentration in the range of about 0.01M to about 0.1M.

10

27. The method of Claim 1, wherein the therapeutic dose of the reversibly inactivated acidified fibrinolytic composition is in the range of between about 0.1 mg plasmin/kg body weight and 10.0 mg plasmin/kg body weight.

15

28. The method of Claim 1, wherein the therapeutic dose of the reversibly inactivated acidified fibrinolytic composition is in the range of between about 0.2 mg plasmin/kg body weight and 4.0 mg plasmin/kg body weight.

20

29. The method of Claim 1, wherein the therapeutic dose of the reversibly inactivated acidified fibrinolytic composition is in the range of between about 1.0 mg plasmin/kg body weight and 2.0 mg plasmin/kg body weight.

30. The method of Claim 1, wherein the reversibly inactivated acidified composition is administered by a catheter device.

31. The method of Claim 31, wherein the intravascular catheter is directed to a
vascular occlusion.

5 32. The method of Claim 31, wherein the intravascular catheter delivers the
reversibly inactivated acidified fibrinolytic composition proximal to, or into, a
thrombotic occlusion.

10 33. The method of Claim 31, wherein the intravascular catheter enters the
thrombotic occlusion and the catheter delivers the reversibly inactivated acidified
fibrinolytic composition directly into the thrombotic occlusion.




Fig 1.




Fig 2.




Fig 3.




Fig 4.

Fig. 5







Fig. 6.












Fig 10








Fig. 12

Fig. 13




Fig. 1A





Fig. 15






Fig. 16.





Fig. 19



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/31115

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 9/48, 9/72, 9/68; A61K 38/48

US CL : 424/94.63, 94.64; 435/212, 215, 217

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/94.63, 94.64; 435/212, 215, 217

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, STN

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NOVOKHATNY et al. Thrombolytic potential of locally delivered active plasmin (Pm): In vitro assessment and in vivo comparison with tPA in the rabbit jugular vein thrombosis model. Blood, J of the Am Soc of Hematology. November 1998. Vol. 92, No. 10. Suppl. 2, Abstract 3400. See abstract.	1-4, 14-16 and 27-29
Y	US 4,462,980 A (DIEDRICHSEN et al) 31 July 1984, see col. 6, lines 14-19.	5-13, 17-21 and 30-33
Y	US 5,472,692 A (LIU et al) 05 December 1995, see entire document.	5-13, 17-21 and 30-33
Y	US 5,304,383 A (EIBL et al) 19 April 1994, see abstract.	5-13 and 17-21



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
16 DECEMBER 2000

Date of mailing of the international search report

21 MAR 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230Authorized officer
MICHELE FLOOD
Telephone No. (703) 308-0196
TERRY J. DEY
PARALEGAL SPECIALIST
TECHNOLOGY CENTER 1600
OD

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/31115

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	US 6,139,819 A (UNGER et al) 31 October 2000, see entire document.	1-5 and 21-26